Annual Report

Overview

The report describes Xspray Pharma's 2024 preparations to commercialize Dasynoc in the US, following FDA regulatory challenges and in partnership with EVERSANA. It also expanded its pipeline to four communicated product candidates, including XS025 cabozantinib, while continuing development of XS003 nilotinib. The sustainability section addresses patients, partnerships, employees and the environment, including responsible procurement, energy efficiency and waste reduction. The Group remained pre-commercial, with 27 employees at year-end and no sales reported.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 27 March 2025
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services